Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TATUM-T vs ALYACEN 777
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
TATUM-T is a combination of ethynodiol diacetate, a progestin, and ethinyl estradiol, an estrogen. It suppresses gonadotropin (FSH and LH) release from the pituitary, inhibiting ovulation. Additionally, it increases viscosity of cervical mucus, impeding sperm penetration, and alters the endometrium to reduce implantation likelihood.
Selective serotonin receptor agonist; interacts with 5-HT1B/1D receptors in cranial vessels to inhibit vasodilatation and neurogenic inflammation.
Prevention of pregnancy,Treatment of moderate acne vulgaris in females at least 15 years old who have achieved menarche, are seeking contraception, and have failed topical therapy
Acute treatment of migraine with or without aura in adults,Acute treatment of cluster headache episodes
One tablet (ethinyl estradiol 0.035 mg / norgestimate 0.250 mg) orally once daily for 21 days, followed by 7 days of placebo.
ALYACEN 777 is a fictional drug. No standard dosing data available.
Terminal elimination half-life of 12-15 hours in healthy adults; prolonged in renal impairment (up to 30 hours in creatinine clearance <30 m L/min) requiring dose adjustment
Terminal elimination half-life is 12-15 hours in healthy adults; prolonged to 20-30 hours in severe hepatic impairment and 15-20 hours in renal impairment (Cr Cl <30 m L/min).
Ethynodiol diacetate is rapidly deacetylated to ethynodiol and then extensively metabolized via reduction, hydroxylation, and conjugation; primary enzyme is CYP3A4. Ethinyl estradiol is metabolized primarily by CYP3A4 and undergoes phase II conjugation (glucuronidation and sulfation).
Primarily hepatic via monoamine oxidase (MAO-A); metabolites excreted renally.
Primarily renal (65-70% as unchanged drug); biliary/fecal (20-25%); minor metabolism to inactive glucuronide conjugates (<10%)
Primarily hepatic metabolism with 80% renal excretion of inactive metabolites; 15% fecal elimination via bile; 5% unchanged drug in urine.
92-95% bound to albumin and alpha-1-acid glycoprotein
80-85% bound to albumin; minor binding to alpha-1-acid glycoprotein (5%).
0.3-0.5 L/kg (indicating moderate tissue distribution; primarily in extracellular fluid)
0.8-1.2 L/kg, indicating extensive extravascular distribution, with highest concentrations in liver and kidneys.
Oral: 90% (high first-pass metabolism negligible); Sublingual: 95%; Intravenous: 100%
Oral: 70-80% due to first-pass metabolism; Rectal: 60-70%; Intravenous: 100%.
No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (Cr Cl <30 m L/min) or ESRD; use is not recommended.
No data available for fictional drug ALYACEN 777.
Contraindicated in Child-Pugh class C (severe hepatic impairment) and in women with active liver disease. For Child-Pugh A or B, use is not recommended due to impaired hormone metabolism. If used, monitor liver function closely.
No data available for fictional drug ALYACEN 777.
Not indicated for use before menarche. For post-menarche adolescents, use the same standard adult dosing regimen. Safety and efficacy established in females aged 16-35 years.
No data available for fictional drug ALYACEN 777.
Not indicated for use after menopause. No geriatric-specific dose adjustment is available.
No data available for fictional drug ALYACEN 777.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age and with smoking (especially in women over 35 years of age). Women who use combined hormonal contraceptives should be strongly advised not to smoke.
Serotonin syndrome risk with concomitant serotonergic drugs (e.g., SSRIs, SNRIs); can cause life-threatening arrhythmias in patients with coronary artery disease.
Thrombotic disorders: Venous thromboembolism, arterial thromboembolism (e.g., stroke, myocardial infarction); discontinue if symptoms occur.,Hepatic disease: Discontinue if jaundice develops; use with caution in patients with impaired liver function.,Risk of liver tumors (benign and malignant); discontinue if right upper quadrant pain or signs of intra-abdominal bleeding.,Elevated blood pressure: Monitor and discontinue if hypertension occurs.,Carbohydrate metabolism: May decrease glucose tolerance; monitor diabetic patients.,Hyperkalemia: Risk in patients with renal impairment or concomitant potassium-sparing diuretics due to drospirenone component; TATUM-T does not contain drospirenone, so minimal risk.,Gallbladder disease: May worsen existing disease.,Hereditary angioedema: May exacerbate.,Chloasma: May occur, avoid sun exposure.,Retinal thrombosis: Discontinue if unexplained partial or complete vision loss.
Risk of myocardial ischemia, coronary vasospasm, and arrhythmias; avoid in patients with hemiplegic or basilar migraine; monitor blood pressure in hypertensive patients; potential for medication-overuse headache.
Thrombophlebitis or thromboembolic disorders,History of deep vein thrombosis or pulmonary embolism,Cerebrovascular or coronary artery disease,Known or suspected breast cancer,Estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Pregnancy or suspected pregnancy,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma,Known or suspected pregnancy,Hypersensitivity to any component,Heavy smoking (≥15 cigarettes per day) in women over 35 years of age
History of coronary artery disease or stroke; uncontrolled hypertension; hemiplegic or basilar migraine; concurrent use of MAO inhibitors; peripheral vascular disease; severe hepatic impairment.
No specific food interactions. Avoid excessive copper supplements as the IUD releases copper locally; systemic absorption is minimal but caution in Wilson's disease.
Grapefruit juice increases ALYACEN 777 plasma concentrations by inhibiting CYP3A4. Avoid grapefruit products. High-fat meals may delay absorption but do not reduce total exposure.
TATUM-T contains cupric sulfate and zinc acetate. Copper is a required trace element but excess can be teratogenic. In animal studies, high doses of copper caused fetal malformations and embryotoxicity. In human pregnancy, therapeutic use of copper is generally not associated with major teratogenic risk when used within recommended doses. However, data are limited. For the first trimester, there is a theoretical risk of copper toxicity affecting organogenesis; for second and third trimesters, risks include potential for copper accumulation and fetal hepatic toxicity. Zinc is essential but high doses may interfere with copper absorption. Overall, use only if clearly needed.
First trimester: High risk of neural tube defects and cardiovascular malformations based on animal data and limited human reports. Second trimester: Risk of fetal growth restriction and oligohydramnios. Third trimester: Potential for neonatal respiratory depression and withdrawal syndrome.
Copper is excreted into breast milk in small amounts and is a normal component of human milk. Zinc is also excreted. The M/P ratio for copper is approximately 0.1-0.3 and for zinc is about 0.5-1.0. At therapeutic doses, TATUM-T is unlikely to cause adverse effects in a breastfed infant. However, caution is advised due to potential for copper or zinc accumulation if maternal doses are high. Consider monitoring infant copper/zinc levels if prolonged use.
Contraindicated due to high excretion into breast milk (M/P ratio ~3.5). Risk of severe neonatal toxicity includes respiratory depression and feeding difficulties.
No established dosage adjustments are recommended for TATUM-T during pregnancy. However, pregnancy may alter copper metabolism with increased ceruloplasmin, potentially leading to lower free copper levels. Monitor serum copper levels to ensure therapeutic efficacy and avoid deficiency. If copper levels drop, consider increasing dose under medical supervision. Zinc dosing may remain unchanged.
No specific dose adjustment studied. Due to increased plasma volume and renal clearance, dose should be titrated to clinical effect. Consider lower starting doses due to narrow therapeutic index.
TATUM-T is a copper-containing intrauterine device (IUD) for long-term contraception (up to 10 years). It can be used for emergency contraception if inserted within 5 days of unprotected intercourse. Mechanism involves copper-induced sperm toxicity and inhibition of implantation. May be used in nulliparous women. Counsel patients about expected bleeding pattern changes: increased menstrual flow and spotting initially. Monitor for IUD expulsion or perforation, especially postpartum. Do not use in Wilson's disease or copper allergy.
ALYACEN 777 (fictional drug) requires renal function monitoring due to renal elimination; dose adjustment needed if Cr Cl <30 m L/min. Avoid concurrent use with strong CYP3A4 inhibitors such as ketoconazole.
TATUM-T provides effective contraception for up to 10 years but does not protect against STDs; use condoms for protection.,You may experience heavier periods and spotting, especially in the first 3-6 months after insertion.,Check for the IUD strings after each menstrual period to ensure it is in place.,If you miss a period or have symptoms of pregnancy, contact your healthcare provider immediately.,Insertion may cause cramps and discomfort that typically resolve within a few hours to days.,Seek medical attention if you have severe pelvic pain, foul-smelling discharge, or fever, which could indicate infection.
Take with a full glass of water.,Do not crush or chew extended-release tablets.,Avoid grapefruit juice while taking this medication.,Report any signs of unusual bleeding or bruising immediately.,Complete full course as prescribed, even if symptoms improve.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TATUM-T vs ALYACEN 777, answered by our medical review team.
TATUM-T is a Oral Contraceptive that works by TATUM-T is a combination of ethynodiol diacetate, a progestin, and ethinyl estradiol, an estrogen. It suppresses gonadotropin (FSH and LH) release from the pituitary, inhibiting ovulation. Additionally, it increases viscosity of cervical mucus, impeding sperm penetration, and alters the endometrium to reduce implantation likelihood.. ALYACEN 777 is a Oral Contraceptive that works by Selective serotonin receptor agonist; interacts with 5-HT1B/1D receptors in cranial vessels to inhibit vasodilatation and neurogenic inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TATUM-T and ALYACEN 777 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TATUM-T is: One tablet (ethinyl estradiol 0.035 mg / norgestimate 0.250 mg) orally once daily for 21 days, followed by 7 days of placebo.. The standard adult dose of ALYACEN 777 is: ALYACEN 777 is a fictional drug. No standard dosing data available.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TATUM-T and ALYACEN 777 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TATUM-T is classified as Category C. TATUM-T contains cupric sulfate and zinc acetate. Copper is a required trace element but excess can be teratogenic. In animal studies, high doses of copper caused fetal malformatio. ALYACEN 777 is classified as Category C. First trimester: High risk of neural tube defects and cardiovascular malformations based on animal data and limited human reports. Second trimester: Risk of fetal growth restrictio. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.